Home News Page 66

News

Catalent receives 11th annual CPhI live Pharma Award

CPhI Worldwide, organized by UBM Live, announced the winners of the 11th annual CPhI live Pharma Awards. The annual...

Ongoing Development of Inotuzumab Ozogamicin in Hematological Malignancies

The mechanism of action of calicheamicin, a DNA-damaging agent that, following intracellular activation, binds to DNA in the minor...

Oxford BioTherapeutics and Berlin Chemie Develop New Antibody-Drug Conjugate as Second Clinical Development Candidate...

Oxford BioTherapeutics, a biopharmaceutical company developing a range of innovative antibody-drug conjugates or ADCs based on the company's proprietary...

Catalent Pharma Solutions Inc. acquires Redwood Bioscience Inc

Leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, Catalent Pharma...

Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer

The glycoprotein NMB or gpNMB, a novel transmembrane protein which is overexpressed in 40% to 60% of breast cancers,...

What is the Potential of Antibody-based Therapies for Myeloma?

Optimal target antigen selection antibody-based therapeutics can be very effective agents for the treatment of hematologic malignancies. However, there...

Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering

Baxter’s BioPharma Solutions (BPS) business and Sigma-Aldrich Corporation’s SAFC® Custom Manufacturing Services business unit, have established a collaborative manufacturing...

Merck KGaA acquires Sigma-Aldrich

Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono...

A Successful Liaison between Chemistry and Biology

The development of new therapies for the treatment of human diseases is arguably one of the most important roles...

Sutro Biopharma and Merck Partner in Developing of Antibody Drug Conjugates

Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA,...